Beamion's Zongertinib Receives FDA Accelerated Approval for HER2-Mutant NSCLC as LUNG-1 Study Results Published in NEJM
Decision brief
Answer first · skim in under a minute
Beamion's zongertinib gains FDA accelerated approval for HER2-mutant NSCLC treatment following breakthrough therapy designation and NEJM publication.
Key questions this brief answers
- What is zongertinib approved for?
- What were the results of the Beamion LUNG-1 trial?
- When was zongertinib approved by the FDA?
- How do patients qualify for zongertinib treatment?
The FDA granted accelerated approval to zongertinib on August 8, 2025, for adults with HER2-mutant non-small cell lung cancer, based on the Beamion LUNG-1 trial showing a 75% objective response rate in previously treated patients.
Contents10 sections
Key Takeaways
- FDA granted accelerated approval to zongertinib on August 8, 2025, for HER2-mutant NSCLC with confirmed HER2 tyrosine kinase domain mutations
- Beamion LUNG-1 trial (NCT04886804) demonstrated 75% ORR in patients previously treated with platinum-based chemotherapy
- 58% of responders maintained response for 6 months or longer per NEJM publication of LUNG-1 results
- FDA-approved companion diagnostic: Oncomine Dx Target Test for patient selection
What Did the FDA Approve?
The U.S. Food and Drug Administration approved zongertinib (brand name Hernexeos) for treating adult patients with unresectable or metastatic non-squamous non-small cell lung cancer whose tumors harbor HER2 (ERBB2) tyrosine kinase domain activating mutations. This approval marks the first targeted therapy specifically indicated for this molecular subset of lung cancer patients.
The approval requires use of an FDA-authorized companion diagnostic test to identify eligible patients. The Oncomine Dx Target Test received concurrent approval for detecting HER2 TKD mutations in NSCLC tumor tissue.
What Were the Beamion LUNG-1 Trial Results?
The accelerated approval rests on data from the Beamion LUNG-1 trial (NCT04886804), a multi-cohort Phase 1 study sponsored by Boehringer Ingelheim. Results published in the New England Journal of Medicine established zongertinib's efficacy profile.
In the primary efficacy population of 71 patients previously treated with platinum-based chemotherapy, investigators recorded a 75% objective response rate (95% CI: 63–83). The median duration of response reached 14.1 months, with 58% of responders maintaining response for 6 months or longer.
A secondary cohort of 34 patients previously treated with both platinum chemotherapy and a HER2-targeted antibody-drug conjugate showed a 44% response rate (95% CI: 29–61), with median duration of response of 5.4 months.
How Does Zongertinib Work?
Zongertinib is an oral, irreversible tyrosine kinase inhibitor that selectively targets HER2 (ERBB2) mutations. Unlike HER2-targeted therapies developed primarily for breast cancer, zongertinib was designed specifically for the mutations found in lung cancer.
HER2 mutations occur in approximately 2–4% of NSCLC cases. These alterations cluster in the tyrosine kinase domain and drive constitutive signaling that promotes tumor growth. Zongertinib binds irreversibly to the mutant kinase, blocking downstream signaling pathways.
What Is the Regulatory Status?
The FDA granted accelerated approval through its Accelerated Approval Program, which allows earlier approval for drugs treating serious conditions based on surrogate endpoints reasonably likely to predict clinical benefit. Continued approval depends on verification of clinical benefit in confirmatory trials.
Zongertinib previously received Breakthrough Therapy designation and Fast Track designation, programs designed to expedite development of drugs addressing unmet medical needs. The approval followed standard FDA review timelines despite these expedited designations.
What Is the Confirmatory Trial?
The accelerated approval requires verification through the ongoing Beamion LUNG-2 trial, a randomized controlled study comparing zongertinib to standard-of-care pembrolizumab plus platinum-based chemotherapy in treatment-naïve patients with HER2-mutant NSCLC. This trial will measure progression-free survival as its primary endpoint, with overall survival as a secondary measure.
Primary completion for Beamion LUNG-2 is estimated for late 2027. If the trial confirms clinical benefit, the FDA will convert the accelerated approval to traditional approval.
What Is the Dosing and Safety Profile?
The approved dosing regimen uses body weight:
- 120 mg orally once daily for patients weighing less than 90 kg
- 180 mg orally once daily for patients weighing 90 kg or more
Prescribing information includes warnings for hepatotoxicity, left ventricular dysfunction, interstitial lung disease/pneumonitis, and embryo-fetal toxicity. The most common adverse reactions include diarrhea, increased ALT and AST, and nausea.
How Does This Change Treatment?
Before zongertinib's approval, patients with HER2-mutant NSCLC had no FDA-approved targeted therapies specific to this indication. Treatment typically involved platinum-based chemotherapy or enrollment in clinical trials.
The approval establishes molecular testing for HER2 mutations as standard of care in NSCLC workup. Patients with non-squamous NSCLC should now undergo testing to determine eligibility for zongertinib if their disease progresses after initial therapy.
Frequently Asked Questions
What is zongertinib approved for?
Zongertinib is FDA-approved for adults with unresectable or metastatic HER2-mutant non-squamous non-small cell lung cancer whose tumors have HER2 tyrosine kinase domain activating mutations, as detected by an FDA-authorized test.
What were the results of the Beamion LUNG-1 trial?
The Beamion LUNG-1 trial achieved a 75% objective response rate in patients previously treated with platinum-based chemotherapy, with 58% of responders maintaining response for at least 6 months.
When was zongertinib approved by the FDA?
The FDA granted accelerated approval to zongertinib on August 8, 2025, based on data from the Beamion LUNG-1 clinical trial.
How do patients qualify for zongertinib treatment?
Patients must undergo testing with the FDA-authorized Oncomine Dx Target Test to confirm their tumors harbor HER2 tyrosine kinase domain activating mutations before starting zongertinib.
Primary Sources
Regulatory catalyst tracker
Track PDUFA dates, approval milestones, and label updates for zongertinib.
Unlock full calendar →Investor brief
Download a one-page summary of regulatory impact and competitive context.
Explore drug hub →This article follows our editorial standards. Report a correction via editorial contact.
